CSIMarket
 
Yield10 Bioscience Inc   (MBLX)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 2
 Employees 68
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Yield10 Bioscience Inc
Metabolix is an advanced biomaterials company focused on delivering sustainable solutions to the plastics industry. We have core capabilities in microbial genetics, fermentation process engineering, chemical engineering, polymer science, plant genetics and botanical science, and we have assembled these capabilities in a way that has allowed us to integrate our biotechnology research with real world chemical engineering and industrial practice. In addition, we have created an extensive intellectual property portfolio to protect our innovations which, together with our technology, serves as a valuable foundation for our business.
Metabolix was formed to leverage the ability of natural systems to produce complex biopolymers from renewable resources. We have focused on a family of biopolymers found in nature called polyhydroxyalkanoates (“PHAs”), which occur naturally in living organisms and are chemically similar to polyesters. We have demonstrated the production of our PHAs from pilot to industrial scale and we have sold our PHA products commercially since 2012.
Our targeted markets offer substantial opportunity for innovation and value creation. Our strategy is based on the performance and differentiation of our materials. We aim to address unmet needs of our customers and leverage the distinctive properties of our proprietary PHA biopolymers to improve critical product qualities of material systems and enable our customers to enhance the value of their products and/or achieve cost savings through their value chains. As such, we are positioning our biopolymers as advanced specialty materials that offer a broad and attractive range of product and processing properties compared to other bioplastics or performance additives. We believe that a substantial global market opportunity exists to develop and commercialize our advanced biopolymer product technology.


   MBLX is expected to report next financial results on August 14, 2020.
 

Yield10 Bioscience Inc 's Segments
 
 

Mayville Engineering Company Inc

Logged a Loss, Topline Tumbles

In the second quarter Mayville Engineering Company Inc lost money of $-0.35 per share compared to $-0.91 a year ago and from $0.00 per share from the previous quarter.

Sales fell sharply by -56.88% to $62.58 millions from $145.13 millions in the same quarter a year ago and sequentially Sales Tumbled by -42.38% from $108.61 millions.

Tracon Pharmaceuticals Inc

Deficit Bigger Than a Year Ago but Revenues Unchanged

In the second quarter Tracon Pharmaceuticals Inc loss increased of $-0.70 per share compared to $-0.21 a year ago and improved from $-0.78 per share from the previous quarter.

Sales remained unchanged to $0.00 millions from $0.00 millions in the same quarter a year ago and sequentially from $0.00 millions.

Resonant Inc

Redemption of Losses, Sales more than Double

Resonant Inc announced earnings per share of $-0.14 and Sales of $0.54 millions in the second quarter, Company's decreased loss per share, versus $-0.27 eps, earned in the same quarter a year ago, although Resonant Inc saw it's Sales rise by 858.73% in the same period.

Bellerophon Therapeutics Inc

Bellerophon Therapeutics Inc announced second quarter operating loss of $-5.759 millions

In the second quarter Bellerophon Therapeutics Inc loss increased of $-0.51 per share compared to $-0.06 a year ago and improved from $-1.08 per share from the previous quarter.

Sales remained unchanged to $0.00 millions from $0.00 millions in the same quarter a year ago and sequentially from $0.00 millions.

Falconstor Software Inc

Break-even, Sales Weak

In the second quarter Falconstor Software Inc reached break-even of $0.00 per share compared to $-0.27 a year ago and from $-0.17 per share from the previous quarter.

Sales declined in double digits by -12.5% to $3.50 millions from $4.00 millions in the same quarter a year ago and sequentially Sales advanced by 10.04 % from $3.18 millions.






   
Major Competitors Stock performance

5 Days Decrease / Increase
     
• View Complete Report
   



       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

CTG's Profile

Stock Price

CTG's Financials

Business Description

Fundamentals

Charts & Quotes

CTG's News

Suppliers

CTG's Competitors

Customers & Markets

Economic Indicators

CTG's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071